Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Zacks News
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions
by Zacks Equity Research
ResMed introduces digital and personalized solutions designed to improve sleep health.
3 MedTech Stocks to Buy as Monetary Policy Eases
by Urmimala Biswas
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.
Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock
by Zacks Equity Research
Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.
BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan
by Zacks Equity Research
Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Zacks.com featured highlights General Motors, Boston Scientific and Assurant
by Zacks Equity Research
General Motors, Boston Scientific and Assurant have been highlighted in this Screen of The Week article.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Is HOLX Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Hologic's strength in Molecular Diagnostics is highly promising. Yet, macroeconomic uncertainties can pose headwinds for its operations.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
by Zacks Equity Research
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Boston Scientific (BSX) closed at $83.08 in the latest trading session, marking a -0.5% move from the prior day.
The S&P 500 to Hit 6,000 Soon? Buy 3 Momentum Stocks Now
by Tirthankar Chakraborty
S&P 500 stocks such as General Motors, Boston Scientific, and Assurant have been selected as the momentum picks for the day using the Driehaus strategy.
MDT Stock Might Gain From Expanded AiBLE Ecosystem and New Partnership
by Zacks Equity Research
Medtronic expands AiBLE spine surgery ecosystem with new technologies and a partnership with Siemens Healthineers.
Here's Why You Should Add HAE Stock in Your Portfolio Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
NVIDIA & 2 Other S&P 500 Stocks Show Strong Earnings Growth
by Tirthankar Chakraborty
S&P 500 stocks such as NVIDIA, Boston Scientific and American Water Works are, currently, exhibiting superb earnings growth.
VEEV Stock Down Despite Expansion of Vault QMS to Boost Patient Safety
by Zacks Equity Research
Veeva Systems' addition of new capabilities is likely to improve the timeliness and accuracy of field actions to ensure product quality and patient safety.
Zacks Industry Outlook Highlights Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health
by Zacks Equity Research
Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health are part of the Zacks Industry Outlook article.
Exclusive Partnership With Pair Eyewear Likely to Support EYE Stock
by Zacks Equity Research
National Vision's America's Best stores become the exclusive retail partner of Pair Eyewear.
Should You Continue to Retain LH Stock in Your Portfolio?
by Zacks Equity Research
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
by Zacks Equity Research
AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Senseonics Stock Down Despite New FDA Approval for Eversense 365
by Zacks Equity Research
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
by Zacks Equity Research
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.